This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database


Babai, Samy, Auriche, Pascal, Le-Louët, Hervé


Thérapie, Volume: 65, No.: 3, Pages.: 255-259

Year of Publication



Background: Since donepezil and memantine are currently used for treating Alzheimer’s disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use.; Methods: All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 years were retrospectively analysed.; Results: The most frequent adverse drug reactions with donepezil alone and memantine alone were respectively: bradycardia (10% versus 7%), weakness (5% versus 6%) and convulsions (4% versus 3%).; Conclusion: The most adverse drug events with donepezil and with memantine are associated with elderly people, even if they do not receive any other treatment. Donepezil and memantine have an acceptable safety profile but physicians should take special care when they prescribe any drug known to cause bradycardia or to reduce the epileptogenic threshold.; © 2010 Société Française de Pharmacologie et de Thérapeutique.

Bibtex Citation

@article{Babai_2010, doi = {10.2515/therapie/2010008}, url = {}, year = 2010, month = {may}, publisher = {Elsevier {BV}}, volume = {65}, number = {3}, pages = {255--259}, author = {Samy Babai and Pascal Auriche and Herv{'{e}} Le-Louët}, title = {Comparison of Adverse Drug Reactions with Donepezil versus Memantine: Analysis of the French Pharmacovigilance Database}, journal = {Th{'{e}}rapie} }


adverse effects, aged, aged, 80 and over, alzheimer disease, databases factual, drug therapy, female, france, humans, indans, male, memantine, middle aged, nootropic agents, piperidines, product surveillance postmarketing

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study


Type of Outcomes

Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime